Authors: Balázs Antus and I. Barta2
View More View Less
  • 1 National Korányi Institute of TB and Pulmonology Department of Pulmonology Budapest Hungary
  • | 2 National Korányi Institute of TB and Pulmonology Department of Pathophysiology Pihenő út 1 H-1121 Budapest Hungary
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $752.00

Cross Mark

In a recent trial we have assessed fractional exhaled nitric oxide (FENO) in a cohort of patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD). In the current study we have retrospectively investigated the frequency of severe hospitalization-associated exacerbations in the same cohort over 3 years after the initial FENO measurement. A total of 58 COPD patients were enrolled and allocated either into the low (< 27 ppb) or the high (≥ 27 ppb) FENO group depending on their FENO level at exacerbation. Beside the annual rate of exacerbations, sputum culture results and the frequency of antibiotic treatments were also analyzed during the follow-up. Both the number of exacerbations per patient-year and the hospitalization days due to exacerbations were significantly increased in patients from the low FENO group compared to those from the high FENO group. Sputum samples derived from patients in the low FENO group were more frequently indicative of a bacterial infection compared to those obtained from the other subgroup. Also, the frequency of antibiotic treatments was significantly increased in subjects from the low FENO group. Results of this pilot study suggest that COPD patients have diverse risks for future exacerbations depending on their FENO levels at exacerbation.

  • Agusti A, Sobradillo P, Celli B: Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am. J. Respir. Crit. Care Med. 183, 1129–1137 (2011)

    Celli B , 'Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine ' (2011 ) 183 Am. J. Respir. Crit. Care Med. : 1129 -1137.

    • Search Google Scholar
  • Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR, COPD Clinical Research Network: Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365, 689–698 (2011)

    Anthonisen NR , 'Azithromycin for prevention of exacerbations of COPD ' (2011 ) 365 N. Engl. J. Med. : 689 -698.

    • Search Google Scholar
  • Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106, 196–204 (1987)

    Nelson NA , 'Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease ' (1987 ) 106 Ann. Intern. Med. : 196 -204.

    • Search Google Scholar
  • Antus B, Barta I, Horvath I, Csiszer E: Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology 15, 472–477 (2010)

    Csiszer E , 'Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations ' (2010 ) 15 Respirology : 472 -477.

    • Search Google Scholar
  • Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M: Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 174, 6–14 (2006)

    Saetta M , 'Pulmonary biomarkers in chronic obstructive pulmonary disease ' (2006 ) 174 Am. J. Respir. Crit. Care Med. : 6 -14.

    • Search Google Scholar
  • Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR, Zamel N: Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 138, 682–692 (2010)

    Zamel N , 'Exhaled nitric oxide in pulmonary diseases: a comprehensive review ' (2010 ) 138 Chest : 682 -692.

    • Search Google Scholar
  • Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ: Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356,1480–1485 (2000)

    Wardlaw AJ , 'Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial ' (2000 ) 356 Lancet : 1480 -1485.

    • Search Google Scholar
  • Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing (2010)

    '', in Performance Standards for Antimicrobial Susceptibility Testing , (2010 ) -.

  • Donaldson GC, Wedzicha JA: COPD exacerbations 1: Epidemiology. Thorax 61, 164–168 (2006)

    Wedzicha JA , 'COPD exacerbations 1: Epidemiology ' (2006 ) 61 Thorax : 164 -168.

  • Dummer JF, Epton MJ, Cowan JO, Cook JM, Condliffe R, Landhuis CE, Smith AD, Taylor DR: Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am. J. Respir. Crit. Care Med. 180, 846–852 (2009)

    Taylor DR , 'Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide ' (2009 ) 180 Am. J. Respir. Crit. Care Med. : 846 -852.

    • Search Google Scholar
  • Dummer JF, Taylor DR: Defining the role of exhaled nitric oxide measurements in COPD. Respirology 15, 385–386 (2010)

    Taylor DR , 'Defining the role of exhaled nitric oxide measurements in COPD ' (2010 ) 15 Respirology : 385 -386.

    • Search Google Scholar
  • Fujimoto K, Kubo K, Yamamoto H, Yamaguchi S, Matsuzawa Y: Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest 115, 697–702 (1999)

    Matsuzawa Y , 'Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema ' (1999 ) 115 Chest : 697 -702.

    • Search Google Scholar
  • Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA: Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363, 1128–1138 (2010)

    Wedzicha JA , 'Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease ' (2010 ) 363 N. Engl. J. Med. : 1128 -1138.

    • Search Google Scholar
  • Kunisaki KM, Rice KL, Janoff EN, Rector TS, Niewoehner DE: Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. Ther. Adv. Respir. Dis. 2, 55–64 (2008)

    Niewoehner DE , 'Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study ' (2008 ) 2 Ther. Adv. Respir. Dis. : 55 -64.

    • Search Google Scholar
  • McMullin BB, Chittock DR, Roscoe DL, Garcha H, Wang L, Miller CC: The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated patients in the intensive care unit. Respir. Care 50, 1451–1456 (2005)

    Miller CC , 'The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated patients in the intensive care unit ' (2005 ) 50 Respir. Care : 1451 -1456.

    • Search Google Scholar
  • Miller C, Miller M, McMullin B, Regev G, Serghides L, Kain K, Road J, Av-Gay Y: A phase I clinical study of inhaled nitric oxide in healthy adults. J. Cyst. Fibros. 11, 324–331 (2012)

    Av-Gay Y , 'A phase I clinical study of inhaled nitric oxide in healthy adults ' (2012 ) 11 J. Cyst. Fibros. : 324 -331.

    • Search Google Scholar
  • Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, Dolovich J, Hargreave FE: Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am. J. Respir. Crit. Care Med. 158, 1511–1517 (1998)

    Hargreave FE , 'Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis ' (1998 ) 158 Am. J. Respir. Crit. Care Med. : 1511 -1517.

    • Search Google Scholar
  • Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 176, 532–555 (2007)

    Zielinski J , 'Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary ' (2007 ) 176 Am. J. Respir. Crit. Care Med. : 532 -555.

    • Search Google Scholar
  • Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA: Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 178, 1139–1147 (2008)

    Wedzicha JA , 'Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations ' (2008 ) 178 Am. J. Respir. Crit. Care Med. : 1139 -1147.

    • Search Google Scholar
  • Silverman EK: Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression? Proc. Am. Thorac. Soc. 4, 586–590 (2007)

    Silverman EK , 'Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression? ' (2007 ) 4 Proc. Am. Thorac. Soc. : 586 -590.

    • Search Google Scholar
  • Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R: Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60, 925–931 (2005)

    Ochando R , 'Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease ' (2005 ) 60 Thorax : 925 -931.

    • Search Google Scholar
  • Soter S, Barta I, Antus B: Sputum biomarkers in COPD exacerbations. Eur. Respir. J. 38, S157 (2011)

    Antus B , 'Sputum biomarkers in COPD exacerbations ' (2011 ) 38 Eur. Respir. J. : S157 -.

  • Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC: Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 61, 817–827 (2006)

    Jongste JC , 'Exhaled nitric oxide measurements: clinical application and interpretation ' (2006 ) 61 Thorax : 817 -827.

    • Search Google Scholar
  • Woodruff PG: Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials. Proc. Am. Thorac. Soc. 8, 350–355 (2011)

    Woodruff PG , 'Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials ' (2011 ) 8 Proc. Am. Thorac. Soc. : 350 -355.

    • Search Google Scholar
  • Yoon SS, Coakley R, Lau GW, Lymar SV, Gaston B, Karabulut AC, Hennigan RF, Hwang SH, Buettner G, Schurr MJ, Mortensen JE, Burns JL, Speert D, Boucher RC, Hassett DJ: Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J. Clin. Invest. 116, 436–446 (2006)

    Hassett DJ , 'Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions ' (2006 ) 116 J. Clin. Invest. : 436 -446.

    • Search Google Scholar
All Time Past Year Past 30 Days
Abstract Views 9 9 0
Full Text Views 11 0 0
PDF Downloads 12 0 0